ABSTRACT
Cardio-cerebral vascular diseases endanger people's health very seriously. Thrombolytic therapy is effective in curing thrombotic diseases at present. Microorganism is an important source of thrombolytic drug. Plasminogen activators are widely used as thrombolytic drugs clinically, while they are still exists some defects. This article analyzed research and development status of kinds of thrombolytic drugs from microorganisms, and evaluated their clinical efficacy and safety, aiming at showing the direction to search new and effective thrombolytic drugs and prevent and treat thromboembolic disease.
Subject(s)
Humans , Bacteria , Clinical Protocols , Classification , Drug Discovery , Methods , Drug Therapy, Combination , Methods , Fibrinolytic Agents , Therapeutic Uses , Plasminogen Activators , Therapeutic Uses , Thromboembolism , Drug Therapy , Thrombolytic Therapy , Methods , Thrombosis , Drug Therapy , Urokinase-Type Plasminogen Activator , Therapeutic Uses , Viruses , ChemistryABSTRACT
Objective To Screen out incidence of vitamin K deficiecy and complicated with hemorrhage in newborn patients, infant patients and normal neonates, and also study on the treatment of vitamin K deficiency. Methods Using emzymoimmunoelectrophoresis to test PIVKA Ⅱ in umbilical and vein blood. Results The incidence of vitamin K deficiency in normal neonates, newborn patients (≤ 5 days) and infants patients (25~60 days) are 31.2%,47.6% and 31.8%. The incidence of hemorrhage in newborn patients (≤5 days) is 26.0%, infant patients (25~60 days) is 66.6%. Intramuscular injection of vitamin K 1 1 mg is the proper dosage to prevent and treat vitamin K deficiency. Conclusion The neonates right after birth or about 25 days after birth, especially those of breast feeding and who are getting lievr and gall diseases should receive vitamin K 1 to prevent vitamin K deficiency.